- The OffRoad Re-Entry Catheter System "demonstrated excellent performance in facilitating the treatment of complete blockages in the major arteries that supply blood to the legs," says Boston Scientific (BSX -1.2%). The Re-Route trial showed success in navigating around challenging chronic total occlusions 84.8% of the time, exceeding trial goals.
- More: At 30 days after, 75% of patients experienced an improvement of at least one category in the Rutherford classification. Just 3.3% saw a device-related major adverse event after 30 days - below trial goals.
- Press release.